PIMOZIDE + ANY ANTIPSYCHOTIC vs placebo/no adjunctive treatment + antipsychotics: Global state: relapse medium term (3‐12 months) Clinical diagnoses
PIMOZIDE + ANY ANTIPSYCHOTIC showed no clear difference in global state: relapse medium term (3‐12 months) compared with ANTIPSYCHOTIC + PLACEBO; GRADE not reported.
What each review found
Include earlier review versions| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
PIMOZIDE + ANY ANTIPSYCHOTIC vs ANTIPSYCHOTIC + PLACEBO Global state: relapse medium term (3‐12 months) · patients with schizophrenia or related psychoses PIMOZIDE + ANY ANTIPSYCHOTIC showed no clear difference in global state: relapse medium term (3‐12 months) compared with ANTIPSYCHOTIC + PLACEBO; GRADE not reported. Pimozide for schizophrenia or related psychoses (2013) · Cochrane Headline outcomes only | RR 0.64 [0.37, 1.1] | 4 studies · 507 participants | GRADE not reported |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Pimozide for schizophrenia or related psychoses 2013 · Cochrane Headline outcomes only | Not reported | list not extracted yet | Not assessed |
Studies behind the findings
None of these reviews ties its included studies to this outcome in the data here. Cochrane reviews and reviews with headline outcomes only do not list their studies yet.
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.